The Brigham and Women's Cardiovascular Associates at Care New England offer a variety of clinical trials, with cutting-edge treatments to patients who meet eligibility requirements for specific trials.
ISCHEMIA Study-Enrollment began in September, 2013
This study aims to determine whether an invasive strategy (routine early cardiac catheterization with intent for optimal revascularization) in addition to optimal medical therapy reduces the incidence of the composite of cardiovascular death or nonfatal myocardial infarction compared with a conservative strategy of optimal medical therapy alone (cardiac catheterization and revascularization reserved for patients with refractory angina, ACS, acute ischemic HF or resuscitated cardiac arrest).
- Patients with stable ischemic heart disease and at least moderate ischemia on stress imaging can qualify (nuclear stress test or stress echo).
Who is Excluded?
- History of CABG.
- PCI within the previous 12 months.
- LVEF < 35%.
- History of unprotected left main stenosis >50% on prior coronary computed tomography angiography (CCTA) or prior cardiac catheterization (if available).
- Prior known coronary anatomy unsuitable for either PCI or CABG.
- Unacceptable level of angina despite maximal medical therapy.
- Acute coronary syndrome within the previous 2 months.
RAID Study-Enrollment is expected to begin in April, 2014
This study aims to determine whether ranolazine administration will decrease the likelihood of a composite arrhythmia endpoint consisting of ventricular tachycardia or ventricular fibrillation (VT/VF) requiring ATP therapy, ICD shocks, or death. Patients will receive either ranolazine or placebo during the trial.
The study population will consist of patients with ischemic or non-ischemic cardiomyopathy with existing devices (ICD/CRT-D) and meet the criteria listed below:
RELAX-2 Study-Enrollment is expected to begin April, 2014
The purpose of this study is to evaluate the efficacy, safety, and tolerability of IV serelaxin when added to standard therapy in acute heart failure (AHF) patients. The primary objective is to demonstrate that serelaxin is superior to placebo in reducing CV death in acute heart failure patients during a follow-up period of 180 days.
The study population will consist of patients admitted to the hospital for AHF with mild to moderate renal impairment. Patients will be randomized within 16 hours from presentation to hospital/ER.
Ranolazine Mediated PVC Reduction in Ischemic Heart Disease Study-Enrollment is expected to begin in April, 2014
This is an Investigator Sponsored Research (ISR) program funded by Gilead Sciences. The purpose of this study is to determine if Ranolazine, through a reduction in PVC burden, can manifest beneficial effects on coronary ischemia.
- History of ischemic heart disease (prior bypass or coronary stenting, documentation on cardiac catheterization, nuclear SPECT imaging, cardiac MR, stress echocardiography, or exercise stress testing).
- Elevated PVC burden (1%) on prior Holter/event monitor in previous 12 months or evidence for PVC(s) on baseline ECG within prior 12 months.
For more information on any of these studies or to see if you qualify please call (401) 681-4996.